

FIGURE 1

	10	20	30	40	50	52A	60
J20.8		GGSLKLS	CAASGFTFS	YAMSWVRQT	PAKRL	EWVAVIS	RGGGIFYQDSIKGRFTI
F4.1		ET					VST--S-TV---
F14.6		ALVKP		N-G	E	A	YS--L-V---
H9.3		ELVR	--A-V-V-CTT	--NIKDDYIH	--R-EQG	--IGR-DPAN	--KTK-APKFQDKA--
A2.1		GLVKP	--A-V-V-NV	--YS-TG-F-N	--SHG-S	--GR-NPLN	--DTF-NQKF--KA-L

	70	80	ABC	90
J20.8	ARDNAKNTLYLQ	MSSLSRSED	TAMYCTREKY	..GKRG.MDYWGQTSVTVSS
F4.1	S	---	S	---
F14.6	S	---	R	---
H9.3	TA-TSS	--A--L--T	--V--S	--SNYYGNSPSWFA--
A2.1	TV-KSS	--AHMELR--K--NS-V--CA	GL... T-WYF-V	--A--T--L-A

FIGURE 2



CDR2


YISRGGGIFYYQDSIKG  
-----VST--S-TV--  
A-----YS--L--V--

CDR3

EKYGKRG	MDY (J20.8)
QKYNKRA	MDY (F4.1)
TARATWDW	FAY (F14.6)

FIGURE 3

**Réponse anti-streptavidine****FIGURE 4A****Réponse anti-peroxydase****FIGURE 4B**

FIGURE 5




FIGURE 6





FIGURE 7



□ pLK<sub>19</sub>  
□ CW-K<sub>19</sub>  
■ K<sub>19</sub>-P3  
▨ PEI

FIGURE 8A




FIGURE 8B






FIGURE 9A





FIGURE 9B


ACTIVITE ANTIVIRALE DES  
ANTICORPS ANTI-ADN

FIGURE 10

FIGURE 11A


TITRES INFECTIEUX AU JOUR 13  
Exp III

FIGURE 11B

Titres infectieux au jour 13  
Exp V





FIGURE 11C






FIGURE 12




FIGURE 13A




FIGURE 13B




FIGURE 13D




FIGURE 13C